Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.

Mantovani, Giovanni; Ghiani, M.; Lai, P.; Macciò, Antonio; Dessì, Daniela; Succu, G; Massa, D.; Curreli, L.; Mulas, Carlo; Esu, S.; Proto, E; Cadeddu, Giovanna; Töre, G

doi:10.3892/or.5.6.1499

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of late, agents such as Ifosfamide, taxanes, gemcitabine have been tried. Ifosfamide has shown promising results in various phase II studies on Head and Neck Cancer [9][10][11]. Shin et al used Ifosfamide in combination with platinum compounds and Paclitaxel in locally advanced, metastatic, and recurrent head and neck cancers [12,13].…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Ifosfamide-based chemotherapy in locoregionally advanced nasopharyngeal cancer: evaluation of its role as neoadjuvant chemotherapy

et al. 2008

View full text Add to dashboard Cite

The use of Ifosfamide-based chemotherapy in primary nasopharyngeal carcinoma (NPC), in neoadjuvant settings [NACT] has not been sufficiently evaluated. We present here a retrospective analysis of 78 patients of untreated, locoregionally advanced NPC patients who received Ifosfamide-Cisplatin-based NACT at our institute from 1997 to 2004. Definitive treatment comprised radical radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) using weekly Cisplatin. Post-NACT, 92% patients had a partial response (PR) while 3% had a complete locoregional response (CR). The rates of CR increased to 87% after completion of definitive treatment. With follow up (38 months), 29% patients developed recurrent/persistent disease. The local and locoregional control rates at 5 years were 76% and 73%, respectively. The 5-year overall survival (OAS) was 80% and disease-free survival was 65%. Grade III or more neutropenia was seen in 15%. Results of Ifosfamide-Cisplatin combination as a NACT in advanced NPC have been quite encouraging and need to be exploited further.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Ifosfamide has been used in head and neck malignancies with encouraging results and acceptable toxicity [9][10][11][12][13]. Its use in nasopharyngeal cancer has been mainly restricted to salvage treatment for recurrent or metastatic cases, either as a single agent or in combination with other chemotherapeutic agents [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Ifosfamide-based chemotherapy in locoregionally advanced nasopharyngeal cancer: evaluation of its role as neoadjuvant chemotherapy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Recently, combined radio-chemotherapy or neoadjuvant combined radio-chemotherapy followed by surgery had been able to improve overall survival and locoregional disease control [1,2,11,24,31,37]. Hemoglobin levels are currently the focus of interest as a prognostic factor in patients with head and neck cancer [4,5,8,12,15,34].…”

Section: Wagner W Et Al Hemoglobin Levels In Head and Neck Cancer Pmentioning

confidence: 99%

“…Although up to now the best chemotherapeutic agents and combinations and the optimal rate to integrate chemotherapy with irradiation are still not defined [1]. Ifosfamid has a well known influence on remission rate in patients with head and neck cancer and there are some informations that the impact on survival is not minor than in comparison to 5-FU [20,24,36].…”

Section: Wagner W Et Al Hemoglobin Levels In Head and Neck Cancer Pmentioning

confidence: 99%

Prognostic Value of Hemoglobin Concentrations in Patients with Advanced Head and Neck Cancer Treated with Combined Radio-Chemotherapy and Surgery

et al. 2000

View full text Add to dashboard Cite

In our study hemoglobin level after radio-chemotherapy was identified for the first time to be also a significant prognostic factor (univariate analysis) in head and neck cancer patients who underwent combined radio-chemotherapy. Besides chemotherapy plus low-dose irradiation achieved similar results in comparison with radical resection and high-dose radiotherapy at least for the first 2 years after therapy. Relapsing disease could be treated with 1 additional course of radiotherapy which is supposed to be well tolerated.

show abstract

“…1,2 Because the inhibitory effects of chemotherapy for head and neck cancers are currently assessed by tumor size, clinical 3,4 or in vivo experimental studies 5,6 of anticancer agents have primarily been carried out by obtaining rates of tumor size reduction. Few drugs have been investigated with regard to their effects on cancer invasion and metastasis.…”

mentioning

confidence: 99%

Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice

et al. 2001

View full text Add to dashboard Cite

show abstract

Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.

Cited by 7 publications

References 0 publications

Ifosfamide-based chemotherapy in locoregionally advanced nasopharyngeal cancer: evaluation of its role as neoadjuvant chemotherapy

Ifosfamide-based chemotherapy in locoregionally advanced nasopharyngeal cancer: evaluation of its role as neoadjuvant chemotherapy

Prognostic Value of Hemoglobin Concentrations in Patients with Advanced Head and Neck Cancer Treated with Combined Radio-Chemotherapy and Surgery

Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice

Contact Info

Product

Resources

About